Skip to main content
. 2022 Dec 20;7(7):1168–1177. doi: 10.1182/bloodadvances.2022008460

Figure 1.

Figure 1.

Response outcomesover time for all patients. The best overall response per IMWG uniform response criteria 2016 after lete-cel administration in the mITT population, including all patients who received lete-cel. ∗Pembrolizumab initiation was delayed to week 6 in patients 4 and 6 due to ongoing AEs; †Pending decision to transfer to long-term follow-up study (NCT03391778) at time of data cutoff. IMWG, International Myeloma Working Group; mITT, modified ITT.